Top 3 Canadian Biotech Stocks To Watch In October 2026

Oil prices have jumped to a five month high as fresh attacks on key Middle Eastern energy routes keep inflation risks alive and central banks on edge. Higher fuel costs tend to squeeze broad equity markets, which can push some investors toward sectors driven more by scientific breakthroughs than economic cycles. This article walks through three Canadian biotech stocks from our quality focused screener that aim to offer exactly that kind of differentiated exposure.

The three stocks covered below are only a small sample from this biotech theme, and the full screen surfaced six more Canadian healthcare names with equally compelling stories that are not included here. To identify your own highest conviction ideas across the full results, head straight into the Biotech Stocks screener.

Bright Minds Biosciences (CNSX:DRUG)

Overview: Bright Minds Biosciences is a neuroscience focused biotech developing serotonin 5-HT2 receptor drug candidates for severe epilepsies and neuropsychiatric disorders.

Market Cap: CA$782 million

Bright Minds Biosciences fits the Biotech Stocks theme as a pure clinical stage bet on serotonin based epilepsy and neuropsychiatric treatments. In this case, value depends more on trial results than on current sales. The stock may appeal to investors who are comfortable with higher risk and who are seeking potential upside linked to successful Phase 2 data and follow on studies, with outcomes influenced by how one unseen pressure around future funding terms develops.

That funding overhang is exactly what you need to stress test with the Bright Minds Biosciences financial health report and see how much runway Bright Minds Biosciences really has.

Cronos Group (TSX:CRON)

Overview: Cronos Group is a cannabinoid focused business that cultivates cannabis and develops branded cannabis and cannabinoid products across several international markets.

Operations: Cronos Group generates about $179 million from cultivating, manufacturing, and marketing cannabis products, with revenue mainly from Canada and Israel.

Market Cap: CA$1.7b

Cronos Group matters for this biotech themed screen because its cannabinoid R&D, genetics program, and greenhouse platforms all feed directly into regulated, higher value cannabis products rather than relying solely on broad consumer trends.

"The acquisition of CanAdelaar B.V., which gives Cronos Group control of the largest operator in the Netherlands legal adult use pilot and the only industrial scale greenhouse cultivator in that program, creates a new regulated channel where Canadian product IP and cultivation know how can be applied to add incremental revenue and gross profit from a market that is not yet reflected in historical results."

From here, an important consideration is how that quiet shift in where the highest quality volume is grown and sold may affect future margins.

That margin story is just the starting point. The full narrative for Cronos Group shows how Cronos Group’s shifting mix, capital allocation, and risks all intersect next.

Green Thumb Industries (CNSX:GTII)

Overview: Green Thumb Industries manufactures and sells cannabis-based consumer products and operates medical and adult-use dispensaries across the United States.

Operations: Green Thumb Industries generates about $846 million from Retail and $681 million from Consumer Packaged Goods, almost entirely in the United States.

Market Cap: CA$1.9b

Green Thumb Industries matters for this biotech themed screen because its cannabinoid rich product portfolio depends on extraction, formulation, and quality controlled production more than broad consumer cycles.

"Continued federal rescheduling progress and Green Thumb Industries’ DEA registrations for medical operations create scope for lower effective tax rates and cheaper financing over time, which could lift net margins and earnings power beyond what current models assume."

One key question is what happens if a tightly watched shift in how that cannabinoid engine is taxed and financed breaks in investors’ favor.

If that tax and financing shift is what you are watching, read the full narrative for Green Thumb Industries to see how the scenario set for Green Thumb Industries could be priced in.

Seeking Fresh Alternatives Beyond Biotech?

Fresh ideas move first. Breakout themes, shifting momentum, and under the radar stocks can get caught quickly once the crowd arrives. Scan these curated shortlists to research potential opportunities at an early stage.

• Target consistent income streams by reviewing a curated set of high yield payers through the 3 dividend fortresses before yields decline due to renewed demand.
• Explore early strength in AI infrastructure by scanning the 55 AI infrastructure stocks while these enablers of computing power may still be flying mostly under the radar.
• Search for durable balance sheets using the list of solid balance sheet and fundamentals (7 results) to focus on businesses with staying power before financial quality becomes fully reflected in valuations.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com